{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T08:38:33Z","timestamp":1783759113509,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T00:00:00Z","timestamp":1625616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T00:00:00Z","timestamp":1625616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UG1DA040314"],"award-info":[{"award-number":["UG1DA040314"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K23DA044324"],"award-info":[{"award-number":["K23DA044324"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["5 UG1 DA013714-18"],"award-info":[{"award-number":["5 UG1 DA013714-18"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UG1DA013720"],"award-info":[{"award-number":["UG1DA013720"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UG1DA040316"],"award-info":[{"award-number":["UG1DA040316"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["5 UG1 DA049436-03"],"award-info":[{"award-number":["5 UG1 DA049436-03"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["U10 DA013714"],"award-info":[{"award-number":["U10 DA013714"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["K01AA023859"],"award-info":[{"award-number":["K01AA023859"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Little is known about prevalence and treatment of OUD among youth engaged in primary care (PC). Medications are the recommended treatment of opioid use disorder (OUD) for adolescents and young adults (youth). This study describes the prevalence of OUD, the prevalence of medication treatment for OUD, and patient characteristics associated with OUD treatment among youth engaged in PC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This cross-sectional study includes youth aged 16\u201325\u00a0years engaged in PC. Eligible patients had\u2009\u2265\u20091 PC visit during fiscal years (FY) 2014\u20132016 in one of 6 health systems across 6 states. Data from electronic health records and insurance claims were used to identify OUD diagnoses, office-based OUD medication treatment, and patient demographic and clinical characteristics in the FY of the first PC visit during the study period. Descriptive analyses were conducted in all youth, and stratified by age (16\u201317, 18\u201321, 22\u201325\u00a0years).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among 303,262 eligible youth, 2131 (0.7%) had a documented OUD diagnosis. The prevalence of OUD increased by ascending age groups. About half of youth with OUD had documented depression or anxiety and one third had co-occurring substance use disorders. Receipt of medication for OUD was lowest among youth 16\u201317\u00a0years old (14%) and highest among those aged 22\u201325 (39%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In this study of youth engaged in 6 health systems across 6 states, there was low receipt of medication treatment, and high prevalence of other substance use disorders and mental health disorders. These findings indicate an urgent need to increase medication treatment for OUD and to integrate treatment for other substance use and mental health disorders.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13722-021-00249-3","type":"journal-article","created":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T11:02:53Z","timestamp":1625655773000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Receipt of medications for opioid use disorder among youth engaged in primary care: data from 6 health systems"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7524-0178","authenticated-orcid":false,"given":"Sarah M.","family":"Bagley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Chavez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan M.","family":"Braciszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Akolsile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise M.","family":"Boudreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwen","family":"Lapham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia I.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Bart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bobbi Jo H.","family":"Yarborough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey H.","family":"Samet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Saxon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca C.","family":"Rossom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid A.","family":"Binswanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark T.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph E.","family":"Glass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine A.","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"PROUD Collaborative","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Szapocznik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane M.","family":"Liebschutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian K.","family":"Ahmedani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethann Mangel","family":"Pflugeisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela L.","family":"Stotts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas F.","family":"Northrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana E.","family":"Horigian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela J.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,7]]},"reference":[{"issue":"23","key":"249_CR1","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1001\/jama.2019.16566","volume":"322","author":"M Olfson","year":"2019","unstructured":"Olfson M, Rossen LM, Wall MM, Houry D, Blanco C. Trends in intentional and unintentional opioid overdose deaths in the United States, 2000\u20132017. JAMA. 2019;322(23):2340.","journal-title":"JAMA"},{"issue":"8","key":"249_CR2","doi-asserted-by":"publisher","first-page":"e186558","DOI":"10.1001\/jamanetworkopen.2018.6558","volume":"1","author":"JR Gaither","year":"2018","unstructured":"Gaither JR, Shabanova V, Leventhal JM. US National trends in pediatric deaths from prescription and illicit opioids, 1999\u20132016. JAMA Netw Open. 2018;1(8):e186558\u2013e186558.","journal-title":"JAMA Netw Open"},{"key":"249_CR3","first-page":"1","volume":"282","author":"SC Curtin","year":"2017","unstructured":"Curtin SC, Tejada-Vera B, Warner M. Drug overdose deaths among adolescents aged 15\u201319 in the United States: 1999\u20132015. NCHS Data Brief. 2017;282:1.","journal-title":"NCHS Data Brief"},{"key":"249_CR4","unstructured":"National Institute on Drug Abuse. Effective treatments for opioid addiction. https:\/\/www.drugabuse.gov\/publications\/effective-treatments-opioid-addiction\/effective-treatments-opioid-addiction. Accessed 16 Apr 2019"},{"issue":"22","key":"249_CR5","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMp1402780","volume":"370","author":"ND Volkow","year":"2014","unstructured":"Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies\u2014tackling the opioid-overdose epidemic. N Engl J Med. 2014;370(22):2063\u20136.","journal-title":"N Engl J Med"},{"issue":"3","key":"249_CR6","doi-asserted-by":"publisher","first-page":"e20161893","DOI":"10.1542\/peds.2016-1893","volume":"138","author":"Committee on Substance Use and Prevention","year":"2016","unstructured":"Committee on Substance Use and Prevention. Medication-assisted treatment of adolescents with opioid use disorders. Pediatrics. 2016;138(3):e20161893\u2013e20161893.","journal-title":"Pediatrics"},{"issue":"4","key":"249_CR7","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/ADM.0b013e3182312983","volume":"5","author":"ML Kraus","year":"2011","unstructured":"Kraus ML, Alford DP, Kotz MM, Levounis P, Mandell TW, Meyer M, et al. Statement of the American Society of Addiction Medicine Consensus Panel on the use of buprenorphine in office-based treatment of opioid addiction. J Addict Med. 2011;5(4):254\u201363.","journal-title":"J Addict Med"},{"key":"249_CR8","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1038\/s41380-018-0094-5","volume":"24","author":"J Ma","year":"2018","unstructured":"Ma J, Bao Y-P, Wang R-J, Su M-F, Liu M-X, Li J-Q, et al. Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis. Mol Psychiatry. 2018;24:1868\u201383.","journal-title":"Mol Psychiatry"},{"key":"249_CR9","first-page":"66","volume-title":"National practice guideline for the use of medications in the treatment of addiction involving opioid use","author":"S Comer","year":"2015","unstructured":"Comer S, Cunningham C, Fishman MJ, Gordon A, Kampman K, Langleben D, et al. National practice guideline for the use of medications in the treatment of addiction involving opioid use. Chevy Case: American Society of Addiction Medicine; 2015. p. 66."},{"issue":"8","key":"249_CR10","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1111\/add.13363","volume":"111","author":"LA Marsch","year":"2016","unstructured":"Marsch LA, Moore SK, Borodovsky JT, Solhkhah R, Badger GJ, Semino S, et al. A Randomized controlled trial of buprenorphine taper duration among opioid-dependent adolescents and young adults. Addict Abingdon Engl. 2016;111(8):1406\u201315.","journal-title":"Addict Abingdon Engl"},{"issue":"17","key":"249_CR11","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1001\/jama.2008.574","volume":"300","author":"GE Woody","year":"2008","unstructured":"Woody GE, Poole SA, Subramaniam G, Dugosh K, Bogenschutz M, Abbott P, et al. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. JAMA. 2008;300(17):2003\u201311.","journal-title":"JAMA"},{"issue":"11","key":"249_CR12","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1001\/jamapediatrics.2018.2143","volume":"172","author":"SE Hadland","year":"2018","unstructured":"Hadland SE, Bagley SM, Rodean J, Silverstein M, Levy S, Larochelle MR, et al. Receipt of timely addiction treatment and association of early medication treatment with retention in care among youths with opioid use disorder. JAMA Pediatr. 2018;172(11):1029\u201337.","journal-title":"JAMA Pediatr"},{"issue":"8","key":"249_CR13","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1001\/jamapediatrics.2017.0745","volume":"171","author":"SE Hadland","year":"2017","unstructured":"Hadland SE, Wharam J, Schuster MA, Zhang F, Samet JH, Larochelle MR. Trends in receipt of buprenorphine and naltrexone for opioid use disorder among adolescents and young adults, 2001\u20132014. JAMA Pediatr. 2017;171(8):747\u201355.","journal-title":"JAMA Pediatr"},{"issue":"3","key":"249_CR14","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1001\/jama.2019.18913","volume":"323","author":"M Olfson","year":"2020","unstructured":"Olfson M, Zhang V(, Schoenbaum M, King M. Trends in buprenorphine treatment in the United States, 2009\u20132018. JAMA. 2020;323(3):276.","journal-title":"JAMA"},{"issue":"1","key":"249_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13722-021-00218-w","volume":"16","author":"CI Campbell","year":"2021","unstructured":"Campbell CI, Saxon AJ, Boudreau DM, Wartko PD, Bobb JF, Lee AK, et al. PRimary Care Opioid Use Disorders treatment (PROUD) trial protocol: a pragmatic, cluster-randomized implementation trial in primary care for opioid use disorder treatment. Addict Sci Clin Pract. 2021;16(1):9.","journal-title":"Addict Sci Clin Pract"},{"key":"249_CR16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jsat.2020.02.001","volume":"112S","author":"D Boudreau","year":"2020","unstructured":"Boudreau D, Lapham G, Johnson E, Bobb J, Matthews A, McCormack J, et al. Documented opioid use disorder and its treatment in primary care patients across six U.S. health systems. J Subst Abuse Treat. 2020;112S:41\u20138.","journal-title":"J Subst Abuse Treat"},{"key":"249_CR17","doi-asserted-by":"publisher","first-page":"107732","DOI":"10.1016\/j.drugalcdep.2019.107732","volume":"207","author":"G Lapham","year":"2020","unstructured":"Lapham G, Boudreau DM, Johnson EA, Bobb JF, Matthews AG, McCormack J, et al. Prevalence and treatment of opioid use disorders among primary care patients in six health systems. Drug Alcohol Depend. 2020;207:107732.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"249_CR18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.annemergmed.2019.07.030","volume":"75","author":"SM Bagley","year":"2020","unstructured":"Bagley SM, Larochelle MR, Xuan Z, Wang N, Patel A, Bernson D, et al. Characteristics and receipt of medication treatment among young adults who experience a nonfatal opioid-related overdose. Ann Emerg Med. 2020;75(1):29\u201338.","journal-title":"Ann Emerg Med"},{"issue":"2","key":"249_CR19","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1016\/j.jadohealth.2017.11.033","volume":"62","author":"SE Hadland","year":"2018","unstructured":"Hadland SE, Bagley SM, Rodean J, Levy S, Zima BT. Use of evidence-based medication treatment among medicaid-enrolled youth with opioid use disorder, 2014\u20132015. J Adolesc Health. 2018;62(2):S16.","journal-title":"J Adolesc Health"},{"issue":"3","key":"249_CR20","doi-asserted-by":"publisher","first-page":"e195183","DOI":"10.1001\/jamapediatrics.2019.5183","volume":"174","author":"RH Alinsky","year":"2020","unstructured":"Alinsky RH, Zima BT, Rodean J, Matson PA, Larochelle MR, Adger H, et al. Receipt of addiction treatment after opioid overdose among medicaid-enrolled adolescents and young adults. JAMA Pediatr. 2020;174(3):e195183\u2013e195183.","journal-title":"JAMA Pediatr"},{"key":"249_CR21","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.drugalcdep.2018.09.020","volume":"194","author":"A Chatterjee","year":"2019","unstructured":"Chatterjee A, Larochelle MR, Xuan Z, Wang N, Bernson D, Silverstein M, et al. Non-fatal opioid-related overdoses among adolescents in Massachusetts 2012\u20132014. Drug Alcohol Depend. 2019;194:28\u201331.","journal-title":"Drug Alcohol Depend"},{"issue":"10118","key":"249_CR22","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","volume":"391","author":"JD Lee","year":"2018","unstructured":"Lee JD, Nunes EV, Novo P, Bachrach K, Bailey GL, Bhatt S, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet Lond Engl. 2018;391(10118):309\u201318.","journal-title":"Lancet Lond Engl"},{"issue":"3","key":"249_CR23","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/ajad.12711","volume":"27","author":"A Bisaga","year":"2018","unstructured":"Bisaga A, Mannelli P, Sullivan MA, Vosburg SK, Compton P, Woody GE, et al. Antagonists in the medical management of opioid use disorders: historical and existing treatment strategies: review-opioid detoxification protocols. Am J Addict. 2018;27(3):177\u201387.","journal-title":"Am J Addict"},{"key":"249_CR24","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jsat.2017.07.001","volume":"85","author":"JR Morgan","year":"2018","unstructured":"Morgan JR, Schackman BR, Leff JA, Linas BP, Walley AY. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. J Subst Abuse Treat. 2018;85:90\u20136.","journal-title":"J Subst Abuse Treat"},{"key":"249_CR25","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.drugalcdep.2019.02.031","volume":"200","author":"JR Morgan","year":"2019","unstructured":"Morgan JR, Schackman BR, Weinstein ZM, Walley AY, Linas BP. Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort. Drug Alcohol Depend. 2019;200:34\u20139.","journal-title":"Drug Alcohol Depend"},{"issue":"11","key":"249_CR26","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1001\/jamapediatrics.2019.3200","volume":"173","author":"N Chadi","year":"2019","unstructured":"Chadi N, Rodean J, Earlywine JJ, Zima BT, Bagley SM, Levy S, et al. Treatment for nicotine use disorder among medicaid-enrolled adolescents and young adults. JAMA Pediatr. 2019;173(11):1103.","journal-title":"JAMA Pediatr"},{"issue":"6","key":"249_CR27","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.jadohealth.2016.12.018","volume":"60","author":"JW Welsh","year":"2017","unstructured":"Welsh JW, Knight JR, Hou SSY, Malowney M, Schram P, Sherritt L, et al. Association between substance use diagnoses and psychiatric disorders in\u00a0an adolescent and young adult clinic-based population. J Adolesc Health Off Publ Soc Adolesc Med. 2017;60(6):648\u201352.","journal-title":"J Adolesc Health Off Publ Soc Adolesc Med."},{"issue":"5","key":"249_CR28","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1001\/archinternmed.2010.541","volume":"171","author":"DP Alford","year":"2011","unstructured":"Alford DP, LaBelle CT, Kretsch N, Bergeron A, Winter M, Botticelli M, et al. Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience. Arch Intern Med. 2011;171(5):425\u201331.","journal-title":"Arch Intern Med"},{"key":"249_CR29","unstructured":"Chou R, Korthuis PT, Weimer M, Bougatsos C, Blazina I, Zakher B, et al. Medication-Assisted Treatment Models of Care for Opioid Use Disorder in Primary Care Settings. Rockville (MD): Agency for Healthcare Research and Quality (US); 2016. (AHRQ Comparative Effectiveness Technical Briefs). http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK402352\/. Accessed 6 Mar 2019"},{"issue":"3","key":"249_CR30","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1001\/jama.2016.9795","volume":"316","author":"B Dunlap","year":"2016","unstructured":"Dunlap B, Cifu AS. Clinical management of opioid use disorder. JAMA. 2016;316(3):338\u20139.","journal-title":"JAMA"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-021-00249-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-021-00249-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-021-00249-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T11:11:36Z","timestamp":1625656296000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-021-00249-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,7]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["249"],"URL":"https:\/\/doi.org\/10.1186\/s13722-021-00249-3","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,7]]},"assertion":[{"value":"7 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Kaiser Permanente Washington Institutional Review Board (IRB), and other sites ceded to the Kaiser Permanente Washington IRB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Yarborough has received support through her institution from Syneos Health to conduct FDA-mandated post-marketing research on the risks of opioid analgesic use. Dr. Schwartz has served as a consultant to Verily Life Sciences.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"46"}}